Clinical Trial Update: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing modified XELOX plus sintilimab versus standard XELOX plus sintilimab as first-line therapy for HER2-negative gastric/gastroesop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastric Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Sintilimab (sintilimab)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastric Cancer | Phase 3 | Status: RECRUITING